Bray v F Hoffman-La Roche Ltd

In the case of Bray v F Hoffman-La Roche Ltd, the primary dispute involved the validity and continuation of a representative proceeding initiated by AAN Australia against various Australian subsidiaries of F Hoffman-La Roche Ltd. The Federal Court was tasked with determining the legitimacy of the representative action under Part IVA of the Federal Court Act and whether the proceedings could continue as such.

The legal issues central to the decision involved the interpretation and application of sections 33C(1), 33H(1), 33M, and 33N of the Federal Court Act, particularly in relation to the definition of group members and the procedural requirements for representative proceedings. The Australian subsidiaries argued that the proceedings should be stayed or dismissed due to deficiencies in the pleadings and the definition of group members. They contended that these deficiencies rendered the representative action impracticable and potentially unjust.

The court, after considering the arguments and the broader objectives of Part IVA, ruled that while there were deficiencies in the pleadings and the definition of group members, the overall intent and rationale of the representative action were valid. The court emphasised that the representative action was necessary to provide practical redress to the group members who shared a common grievance regarding the cartel arrangements. The court dismissed the motions of the Australian subsidiaries and allowed AAN Australia to amend its application and statement of claim, ensuring that the proceedings could continue as a representative action. The court also made orders regarding the costs associated with the motions and the application for security for costs.